Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence

combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence Review (1596) Total Article Views Authors: Borghi C, Santi F Published Date June 2012 Volume 2012:6 Pages 449 - 455 DOI: http://dx.doi.org/10.2147/PPA.S23232 Received: 21 November 2011 Accepted: 22 December 2011 Published: 18 June 2012 Claudio Borghi, Francesca Santi Internal Medicine, Aging and Kidney Disease Department, University of Bologna, Italy Abstract: Hypertension is one of the most important and widespread risk factors for the development of cardiovascular disease. Once, combination therapy was traditionally reserved as a third-line or fourth-line approach in the management of hypertension. However, several major intervention trials in high-risk patient populations have shown that an average of 2–4 antihypertensive agents are required to achieve effective blood pressure control. Combination treatment should be considered as a first choice in patients at high cardiovascular risk and in individuals for whom blood pressure is markedly above the hypertension threshold (eg, more than 20 mmHg systolic or 10 mmHg diastolic), or when milder degrees of blood pressure elevation are associated with multiple risk factors, subclinical organ damage, diabetes, renal failure, or associated cardiovascular disease. A number of clinical trials have demonstrated that a fixed combination of lercanidipine and enalapril has better efficacy and tolerability than monotherapy with either agents. The fixed-dose formulation of lercanidipine–enalapril was well tolerated in all clinical trials, with an adverse event rate similar to that of the component drugs as monotherapy. The advantages of combination therapy include improved adherence to therapy and minimization of blood pressure variability. In addition, combining two antihypertensive agents with different mechanisms of action may provide greater protection against major cardiovascular events and the development of end-organ damage.